Peptide Monograph

Dihexa

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide (Angiotensin IV Analog)

At a Glance

Mechanism of Action

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic analog of angiotensin IV, a metabolite of angiotensin II. It was developed by Joseph Harding and John Wright at Washington State University as part of research into the cognitive-enhancing properties of the angiotensin IV / AT4 receptor system. Dihexa was designed as a metabolically stable, blood-brain barrier (BBB)-permeable derivative with enhanced potency over the parent compound.[1]

The primary molecular mechanism of dihexa is its activity as a potent hepatocyte growth factor (HGF) mimetic. McCoy et al. demonstrated that dihexa binds to the HGF receptor (c-Met), a receptor tyrosine kinase, and activates its downstream signaling cascades. Upon c-Met activation, dihexa triggers the PI3K/Akt and Ras/MAPK/ERK pathways, which drive synaptogenesis (formation of new synaptic connections), neuronal survival, and neurite outgrowth.[1]

In the McCoy et al. study, dihexa was reported to be approximately 10⁷ (ten million) times more potent than BDNF (brain-derived neurotrophic factor) in promoting synaptogenesis in a hippocampal neuron culture assay. This extraordinary potency claim, while published in a peer-reviewed journal (Journal of Pharmacology and Experimental Therapeutics), has not been independently replicated and should be interpreted with appropriate caution given the very early stage of research.[1]

Benoist et al. demonstrated that dihexa is blood-brain barrier permeable, a critical property for a potential cognitive-enhancing compound. The lipophilic modifications (N-hexanoic acid and aminohexanoic acid substitutions) that distinguish dihexa from native angiotensin IV were specifically designed to enhance BBB penetration and metabolic stability.[2]

The proposed cognitive mechanism involves HGF/c-Met-mediated promotion of new synaptic connections in hippocampal and cortical circuits. HGF is a pleiotropic growth factor known to promote neuronal survival, axon growth, and synaptogenesis during development and following neural injury. Dihexa is theorized to harness this pathway to promote synaptic plasticity and enhance cognitive function in adult and aged brains.[1][3]

Evidence Summary

Animal Studies (Single Research Group)

McCoy et al. (2013) published the primary efficacy study in the Journal of Pharmacology and Experimental Therapeutics. Key findings included:[1]

• Dihexa restored cognitive function in rats treated with scopolamine (a cholinergic antagonist that impairs memory formation), as measured by performance on the Morris water maze and other learning tasks.
• Dihexa improved cognitive performance in aged rats (a model of age-related cognitive decline).
• In vitro, dihexa promoted synaptogenesis in hippocampal neuron cultures at concentrations approximately 10⁷-fold lower than BDNF.
• The cognitive effects were blocked by a c-Met inhibitor, confirming the HGF/c-Met pathway as the mechanism of action.

Benoist et al. demonstrated that dihexa crosses the blood-brain barrier in rodent models, supporting the feasibility of systemic (including oral) administration for CNS effects. The study also characterized dihexa's metabolic stability relative to native angiotensin IV peptides.[2]

Additional publications from the Harding/Wright group have characterized aspects of dihexa's pharmacology and the broader angiotensin IV / AT4 receptor system, including its relationship to hepatocyte growth factor signaling.[3][4]

Critical Limitations

The dihexa evidence base has several critical limitations that must be explicitly acknowledged:

• Single research group provenance — All published dihexa data comes from one laboratory. Independent replication by other research groups has not been published, which is a significant concern for the reliability of the findings.
• No human data whatsoever — No Phase I safety trial, no pharmacokinetic study, no dose-finding study, and no efficacy study has been conducted in humans.
• No toxicology or safety studies — Standard preclinical safety pharmacology, genotoxicity, and chronic toxicology studies have not been reported.
• Oncological risk not evaluated — Despite activating one of the most well-characterized oncogenic pathways in cancer biology, no carcinogenicity assessment of any kind has been published.
• Extraordinary potency claim — The 10⁷-fold potency advantage over BDNF is an extraordinary claim that demands extraordinary evidence. Without independent replication, this finding should be treated with skepticism.

Primary Uses (in Research)

Based on the extremely limited preclinical literature, dihexa has been investigated for the following applications:

• Cognitive enhancement / nootropic — The primary proposed application. Dihexa's ability to promote synaptogenesis via HGF/c-Met activation in hippocampal circuits has been demonstrated in rodent models. Improved performance on spatial learning tasks in both scopolamine-treated and aged rats suggests potential procognitive effects.[1]
• Age-related cognitive decline — The demonstration of cognitive improvement in aged rats provides a theoretical basis for application in age-related cognitive impairment, though this is entirely preclinical.[1]
• Neurodegenerative disease research — The synaptogenic and neuroprotective properties of HGF/c-Met activation have generated speculative interest in dihexa for Alzheimer's disease and other neurodegenerative conditions, though no disease-specific research has been conducted.
• HGF/c-Met signaling research tool — As a potent, BBB-permeable c-Met agonist, dihexa has potential utility as a research tool for studying HGF/c-Met signaling in the CNS.[3]

Contraindications

Standard Protocols

Dihexa is lipophilic, which supports theoretical oral bioavailability and blood-brain barrier penetration. Benoist et al. demonstrated BBB permeability in rodent models, and the compound was effective when administered both centrally and peripherally in animal studies.[2] However, human oral bioavailability has never been confirmed, and the reported oral doses (10–20 mg) are based entirely on anecdotal community use with no pharmacokinetic basis.

There is no established cycling protocol, no consensus on optimal duration of use, and no data on chronic dosing safety. Given the oncological concerns associated with chronic c-Met activation, the risk-benefit profile of extended use is particularly uncertain.

Common Stacks & Synergies

Dihexa is occasionally discussed in nootropic community contexts alongside other cognitive-enhancing compounds. There is no published evidence supporting any combination:

• Dihexa + Noopept or Semax — Some nootropic protocols combine dihexa with other neuropeptide-based nootropics. The rationale is that different pro-cognitive mechanisms (synaptogenesis via c-Met, neurotrophic signaling via other pathways) might produce additive effects. No evidence supports this combination.
• Dihexa + Racetams — Combining dihexa with racetam-class nootropics (piracetam, aniracetam) has been discussed in self-experimentation forums. No pharmacological or clinical basis exists for this combination.
• Dihexa + NSI-189 — Combining two experimental neurogenic/synaptogenic compounds. Both have thin evidence bases and unknown safety profiles. The combined risk is entirely uncharacterized.

Preparation & Administration

Dihexa is supplied as a powder or in pre-made solution/capsule form from research chemical suppliers.

Oral Administration

Due to its lipophilic nature, dihexa is commonly administered orally, either as weighed powder in capsules or dissolved in a liquid carrier. Human oral bioavailability has not been confirmed. The lipophilic structure suggests theoretical oral absorption, and the compound was active via peripheral routes in animal studies, but human pharmacokinetics are entirely unknown.[2]

Subcutaneous Injection

Some protocols describe subcutaneous injection. As a small molecule (507 Da), dihexa can be dissolved in bacteriostatic water for injection. Use a 29–31 gauge insulin syringe. For injection technique and sterile procedure, see the Injection Safety Guide.

Intranasal Administration

Intranasal administration has been reported in self-experimentation contexts, theorized to provide more direct CNS delivery by bypassing the blood-brain barrier via the olfactory mucosa. No data supports intranasal as a superior route for dihexa.

Dosing Precision

Because no human pharmacokinetic data exists, the relationship between dose, plasma concentration, and CNS exposure is entirely unknown. The anecdotal doses used in self-experimentation may be grossly above or below any pharmacologically relevant range in humans. Without dose-response data, dosing is fundamentally speculative.

Side Effects & Adverse Events

Primary theoretical safety concerns:

• Tumor promotion and cancer risk — This is the dominant safety concern. The HGF/c-Met pathway is a validated oncogenic driver. Chronic activation of c-Met with an exogenous agonist could promote tumor initiation, growth, invasion, and metastasis. Cancer may not become clinically apparent until months or years after exposure, meaning that short-term self-experimentation without long-term follow-up cannot assess this risk. The pharmaceutical industry has invested billions of dollars developing c-Met inhibitors for cancer treatment; dihexa does the opposite.[3]
• Liver effects — HGF is primarily a hepatic growth factor. c-Met activation in the liver promotes hepatocyte proliferation and survival. In the context of chronic liver disease or subclinical hepatocellular pathology, exogenous c-Met activation could have adverse hepatic consequences.
• Cardiovascular effects — As an angiotensin IV analog, dihexa may have effects on the renin-angiotensin system and cardiovascular regulation that have not been characterized.
• Unknown CNS effects — While the intended effect is synaptogenesis, uncontrolled c-Met activation in the brain could theoretically promote unwanted neural growth, alter neural circuit function, or contribute to glioma development.

Self-reported effects from community use (unverified, very small sample size):

• Perceived cognitive enhancement (the intended effect; subject to placebo bias)
• Headache (occasionally reported)
• Vivid dreams or altered sleep quality
• Anxiety or overstimulation (infrequently reported)

Drug Interactions

No formal drug interaction studies have been conducted. The following theoretical interactions are based on dihexa's known mechanism of action:

• c-Met inhibitors (crizotinib, cabozantinib, capmatinib) — Dihexa would directly antagonize the mechanism of action of c-Met inhibitor cancer therapies. Concurrent use would be pharmacologically contradictory and absolutely contraindicated.
• Anti-cancer therapies (any) — Given the oncogenic potential of c-Met activation, concurrent use with any cancer therapy should be avoided.
• Angiotensin system modulators (ACE inhibitors, ARBs) — As an angiotensin IV analog, dihexa could interact with the renin-angiotensin-aldosterone system. The direction and clinical significance of this interaction is unknown.
• Hepatotoxic medications — Given HGF's hepatic effects, concurrent use with hepatotoxic drugs (acetaminophen at high doses, statins, certain antibiotics) could have unpredictable consequences.
• Other nootropics and CNS-active compounds — The effects of combining dihexa with other CNS-active compounds (stimulants, cholinergic agents, other nootropics) are entirely unknown.

Storage & Handling

Dihexa is a relatively small, stable molecule (507 Da) compared to larger peptides and proteins. Protect from prolonged light exposure and moisture. Store sealed powder in a cool, dry environment. Stability data for dihexa is not publicly available; the recommendations above are based on general small-molecule peptide handling guidelines.

Legal & Regulatory Status

• FDA (United States) — Dihexa is not approved for any indication. It is sold under the research chemical designation "not for human consumption." No investigational new drug (IND) application for dihexa is publicly known. The compound has not entered any stage of the FDA drug approval process.
• WADA (World Anti-Doping Agency) — Dihexa's status under WADA regulation is not explicitly addressed, though it could potentially fall under the S0 (non-approved substances) category of the Prohibited List. Athletes should assume it is prohibited.
• European Union — Not approved as a medicinal product. Regulatory status varies by member state.
• Australia (TGA) — Not approved. Likely classified as a prescription-only substance.
• General regulatory context — Dihexa exists in an essentially unregulated space, with no specific scheduling or regulation in most jurisdictions beyond general research chemical provisions.

Open Questions

The dihexa evidence base has profound, fundamental gaps. Key unresolved questions include:

• Cancer risk is the dominant concern — The HGF/c-Met pathway is one of the most well-validated oncogenic drivers in cancer biology. Whether chronic c-Met activation with dihexa increases cancer risk, and at what dose and duration threshold, is the most important unanswered question. Given the latency of most cancers (years to decades), short-term self-experimentation cannot address this risk.[3]
• Human pharmacokinetics are completely unknown — Oral bioavailability, half-life, volume of distribution, clearance, CNS penetration, and dose-response relationships have not been characterized in humans. Every aspect of human pharmacology is speculative.
• Single research group provenance — All published dihexa data originates from the Harding/Wright laboratory at Washington State University. The absence of independent replication is a significant scientific concern, particularly given the extraordinary potency claims.
• Oral bioavailability unconfirmed in humans — While dihexa's lipophilic structure and rodent data suggest oral bioavailability, this has not been confirmed in humans. The widely used oral dosing route may or may not deliver meaningful systemic and CNS exposure.
• No dose-response data — The anecdotal doses used in self-experimentation (10–20 mg oral, 5–10 mg SubQ) have no pharmacological basis. Effective, safe, or toxic dose ranges in humans are unknown.
• Chronic dosing effects unknown — All published animal studies used relatively short exposure periods. The effects of chronic dihexa administration on CNS function, organ health, and cancer risk have not been studied.

Bibliography

1. McCoy AT, Benoist CC, Wright JW, Harding JW. "Selective AT4 receptor ligands facilitate memory in aged rats and reverse the scopolamine-induced deficit in spatial learning." J Pharmacol Exp Ther. 2013;346(2):284-91. doi:10.1124/jpet.113.206060. PMID:23709115.
2. Benoist CC, Kawas LH, Zhu M, Bhargava TE, Harding JW, Wright JW. "Dihexa metabolic stability and brain penetration." J Pharmacol Exp Ther. 2014;351(1):115-22. doi:10.1124/jpet.114.216002. PMID:25082440.
3. Wright JW, Harding JW. "The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease." J Alzheimers Dis. 2015;45(4):985-1000. doi:10.3233/JAD-142814. PMID:25649658.
4. Harding JW, Wright JW. "Angiotensin IV-mediated signaling and the discovery of small molecule HGF/c-Met mimics as a novel class of anti-dementia agents." Curr Drug Targets. 2017;18(7):835-843. doi:10.2174/1389450117666160818143725. PMID:27538456.